APA (7th ed.) Citation

SA, P., B, X., EE, D., S, F., DD, K., F, M., . . . MM, J. (2024). First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. The oncologist, 29(4), e514. https://doi.org/10.1093/oncolo/oyad338

Chicago Style (17th ed.) Citation

SA, Piha-Paul, et al. "First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors." The Oncologist 29, no. 4 (2024): e514. https://doi.org/10.1093/oncolo/oyad338.

MLA (9th ed.) Citation

SA, Piha-Paul, et al. "First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors." The Oncologist, vol. 29, no. 4, 2024, p. e514, https://doi.org/10.1093/oncolo/oyad338.